The Clinical Pharmacist Practitioner (CPP) is an integral provider in the provision of comprehensive medication management (CMM) services in Mental Health (MH) in the provision of comprehensive medication management (CMM) services throughout the stepped care model of MH services across the continuum of care and how full integration of the CPS provider in team-based settings significantly improves access to care, quality and safety for Veterans.

Key Takeaways include:

- The MH CPP is a core team member providing CMM expertise to our Veterans and MH teams.
- The MH CPP are integrated into all levels of the Stepped Care Model of MH Services Across the Continuum of Care to improve access to care, quality and safety through the provision of CMM services.
- The MH CPP impacts access primarily when utilized as a primary MH provider. There are several strong practices across the VA of MH CPS providers across the continuum of care including Primary Care Mental Health Integration (PCMHI), general MH and BHIP (Behavioral Health Interdisciplinary Program), specialty MH, Residential Rehabilitation Treatment Program (RTTP), and inpatient MH.
- The MH CPP regularly performs suicide risk assessments and evaluations for patients as a component of the care and services provided and applies the principles of team-based care and population management to identify patients who could benefit from CMM services to improve access to care, quality and safety.
- There are 501 CPP practicing in MH at 132 VA facilities. During FY20, there were 415,017 encounters by a MH CPP.
- MH CPP are a well-trained workforce. Previously, in evaluating 360 MH CPP with a scope of practice, 84% completed a Post Graduate Year 1 (PGY1) residency, 61% completed a Post Graduate Year 2 (PGY2) with 59% specifically noting a completed Psychiatric Pharmacy PGY2. In addition, 67% report advanced board certification with 53% of these individuals recognized as Board Certified Psychiatric Pharmacists (BCPP).
- VA graduates over 600 pharmacy residents annually, of which approximately 87 have specialized PGY2 psychiatric pharmacy residency training, who are ready for hiring in July of each year.
- Demand for MH providers with comprehensive medication management expertise will continue to increase across the nation because of increased Veteran care needs in MH. Facilities have a significant opportunity to utilize these highly trained MH CPP to meet this demand.

SEE FOLLOWING SECTION FOR FULL NARRATIVE OF THESE POINTS
**Background**

Providing access to high quality health care is one of the Department of Veterans Affairs (VA) top priorities. This encompasses recovery-oriented, evidence-based mental health (MH) care across the continuum of outpatient, residential and inpatient MH services throughout the country (Figure 1). Comprehensive MH services are delivered in a team-based care delivery setting that promote Veteran-centered, coordinated care and promote Veteran recovery. The MH Clinical Pharmacist Practitioner (CPP) is a core team member providing comprehensive medication management (CMM) expertise to Veterans and the MH team.

Psychiatrist and other MH provider shortages are present across the United States which impact access to provide mental health care to patients. At the same time, there is an increase in MH care needs across the nation. There is an apparent need to transform the MH team to include clinicians focused on providing services to the growing mental health population, hence the expertise of the MH CPP is an asset to increase access to CMM services. The Patient-Centered Primary Care Collaborative published a resource guide in 2012 entitled "Integrating Comprehensive Medication Management to Optimize Patient Outcomes." This guide outlines how pharmacists promote the safe, appropriate, and effective use of medications with a demonstrated return on investment by providing effective medication management. Specific to a psychiatric population, the benefits of incorporating a MH CPP to improve both access and the quality of care to patients with mental illness has been reported in the literature. In a 2013 pilot program, pharmacist-delivered CMM provided for patients with MH disorders was demonstrated to improve clinical outcomes, reduce overall healthcare cost, and improve patient satisfaction. Additionally, in a VA setting, MH CPP on a Primary Care Mental Health Integration (PCMH) team have demonstrated ability to help patients achieve goals as measured by validated clinical rating scales. The MH CPPs’ specialized training makes these individuals experts in psychopharmacology, and practicing at the top of their license as a primary MH provider improves access to high quality medication management. The role of the MH CPP in MH services and the impact on integration of the MH CPP will be highlighted.

**Figure 1:** Stepped Care Model of MH Services Across the Continuum of Care

Role of the MH CPP

The MH CPP is a core team member providing CMM expertise to Veterans and MH teams. MH CPP providers are integrated into all levels of the Stepped Care Model of MH Services Across the Continuum of Care (Figure 1), which includes general and specialty MH clinics, behavioral health clinics embedded in...
primary care known as PCMHI, residential rehabilitation treatment programs (RRTP), specialty MH programs, and on inpatient MH units. The impact of the MH CPP includes improvement in access to care, quality and safety through the provision of medication management services.

The VA CPP is an Advanced Practice Provider authorized, under a scope of practice, to autonomously prescribe and provide CMM services in a variety of practice settings as described in VHA Handbook 1108.11 Clinical Pharmacy Services. The types of activities besides prescribing also include executing therapeutic plans, physical and objective disease assessment, utilizing quantitative mental health instruments for psychotic, mood, cognitive, and other MH disorders to monitor medication effectiveness and MH disease conditions, ordering labs and diagnostic tests, taking independent corrective action for identified drug-induced problems, ordering consults to maximize positive drug therapy outcomes, and obtaining and documenting informed consent for treatments and procedures. These activities focus on treatment appropriateness, effectiveness, safety, and adherence for MH and non-MH conditions.

As a component of the CMM services provided, regularly screens for suicide risk using the comprehensive suicide risk evaluation (CSRE). Patients who have been identified as high risk for suicide benefit from improved access and quality of care delivered by a MH CPP. The MH CPP evaluates a patient’s suicidal ideation, intent, and plan, their protective and risk factors, and documents the determined level of suicide risk. This also includes safety planning. With that information and collaboration with team members as clinically indicated, the MH CPP ensures the patient receives the appropriate intervention according to the severity of their suicidality. Established processes for the MH care team for management of patients determined high risk are critical. The MH CPP collaborates with a psychiatrist or appropriate provider for advanced patient care management beyond the MH CPP’s scope of practice.

**Access Impact**
The MH CPP impacts access primarily when utilized as a primary MH provider. The MH CPP has been utilized in a variety of ways to effectively improve access to care and increase quality outcomes in MH care across our VA facilities and across the continuum of care. The MH CPS provider is also a valued team member for treatment of substance use disorders (SUD) throughout the continuum of care.

The MH CPP meets population metric goals by managing at risk Veterans in their own subset of the team’s panel, but also by seeing hospital discharge Veterans who are identified as a high risk for suicide who require more frequent follow-ups and ensuring that safety plans are completed in a timely manner.

**Quality Impact**
The MH CPP positively impacts multiple quality measures within the VA Strategic Analytics for Improvement and Learning (SAIL) model, which is utilized for internal and external benchmarking related to quality, efficiency and productivity. Metrics the MH CPP impact include not only the population coverage metrics related to access, but also continuity of care, suicide risk screening and evaluation, and experience of care for not only the Veteran, but also the team.

The VA Psychotropic Drug Safety Initiative (PDSI) is a nationwide psychopharmacology quality improvement program with the aim of improving safety and effectiveness of psychopharmacotherapy across VA. Focus areas have included improving psychopharmacologic treatment of older Veterans, improving access to evidence-based pharmacotherapy for Veterans with substance use disorders and most recently, reducing benzodiazepine use in high risk populations. In many facilities the CPP leads the PDSI through identification and management of specific local initiatives. Through the collaboration of MH
CPP with Veteran’s health care teams, there has been a marked improvement in PDSI initiatives.  

A unique role of the MH CPP is in the treatment of female Veterans who are trying to conceive, are currently pregnant, or who are breastfeeding. Forty-two percent of women Veterans cared for by VA are of reproductive age (18-44 y/o), with 46.2% carrying at least one psychiatric diagnosis. As is true in many areas of psychiatric medicine, the literature does not provide definitive answers as to whether a woman who is planning to become pregnant, is pregnant, or is breastfeeding should use psychiatric medications. Careful gathering of personal and family history, awareness of the resources and information available, and inclusion of the Veteran in risk-benefit discussions are crucial elements for assisting a female patient with these decisions. As the medication experts on the team, MH CPP possess the knowledge and training for improving education and care for this population. A MH CPP run pregnancy and lactation clinic provides a much-needed service to Veterans. A Veteran’s primary care, women’s health or mental health provider may request varying levels of assistance from the MH CPP. This can include an e-consult to provide recommendations for treatment planning via chart review only, one-time consultation (such as pre-conception planning), interim management and follow up, and/or providing CMM for the patient during and after her pregnancy.

Consistent with other practitioners, the MH CPP scope of practice may include prescriptive authority for controlled substances when the pharmacist state of licensure allows the practice (i.e., the statutes and regulations that define the terms and conditions of the clinical pharmacist’s license), and the pharmacist performs this function in accordance with Federal law, regulations and VHA policy. There are several states in which CPP are authorized to prescribe controlled substances under their licensure, and in these scenarios the MH CPP may obtain a DEA registration to prescribe controlled substances in accordance with their scope of practice (states as of 6/1/21 include CA, ID, MA, MT, NM, NC, OH, WA, TN). In a few instances, VA pharmacists have obtained a DEA license and been authorized by VA to prescribe controlled substances. When the MH CPP does not have prescriptive authority for controlled substances, they work collaboratively with the MH provider by providing therapeutic recommendations when controlled substances are a component of the therapeutic regimen and/or treatment for the individual Veteran. This similar scenario occurs as well when prescribing and managing clozapine within VA. In fact, a large percentage of patients managed on clozapine are done so by the MH CPP, although due to VA electronic medical record and tracking restrictions the actual prescriptions are written by other providers. The MH CPP is also an interdisciplinary team (IDT) member who serves as a resource for other MH team members on evidence-based pharmacological treatment options.

Current Assessment of Clinical Pharmacy Mental Health Practice

Integrating MH CPP and optimizing those care roles across practice settings improves access to CMM. Nationwide, CPP are integrated into care teams delivering care through a variety of modalities (e.g., in-person, telephone, video, e-consult). In FY20, 4,812 CPP delivered over 6 million patient care encounters. During the same time frame, 501 MH CPP at approximately 132 VA facilities recorded 415,017 patient care encounters. In FY21, there are consistently greater than 115,000 encounters per quarter as described in Figure 2. Modalities of patient care encounters are primarily in-person, with expanding growth in virtual care (Figure 3) in FY20. Interventions identified through the PhARMD (Pharmacists Achieve Results with Medications Documentation) Tool provide information on medication management activities and types of disease states managed (Figures 4 and 5).
Figure 2. Mental Health Patient Care Encounters by a MH CPP and Number of MH CPP by Quarter (Defined by ≥ 25% of the encounters by a CPP in a MH clinic during the quarter)

Figure 3. MH CPP Provider Encounter Modalities FY20
In evaluating 360 MH CPP with a scope of practice, 84% completed a Post Graduate Year 1 (PGY1) residency, 61% completed a Post Graduate Year 2 (PGY2) with 59% specifically noting a completed Psychiatric Pharmacy PGY2. In addition, 67% report advanced board certification with 53% of these individuals recognized as Board Certified Psychiatric Pharmacists (BCPP). VA is the largest trainer of PGY2 psychiatric pharmacy residents, graduating approximately 87 PGY2 Psychiatric Pharmacy Residents.
annually.

**Scalability of CPP in Mental Health**

Taking a unique approach to increase the number of CPP in MH, the PBM CPPO partnered with the Office of Rural Health (ORH) in FY17 to successfully implement an Enterprise Wide Initiative (EWI), Increasing Access to Care for Rural Veterans by Leveraging CPP, known as the CPP Rural Veteran Access (CRVA) initiative. This project aimed to provide greater access to CMM to Veterans living in rural areas in three foundational areas of need: primary care, pain management and mental health. This robust initiative provided funding for the hiring and placement of 37 new MH CPP. After hiring in FY17 and expedited implementation, these MH CPP worked to optimize direct patient care impact providing care for 38,545 Veterans with over 20,000 being Rural Veterans as of June 2020, recording over 130,000 encounters. Due to the success of this initiative, the CRVA Diffusion project hired an additional 15 MH CPP in FY21 and in FY20/FY21 the CRVASUD hired an additional 31 MH CPP. This PBM built infrastructure demonstrates its ability to scale national MH CPP practice expansion successfully and efficiently.

**Conclusions**

MH clinical pharmacy practice continues to demonstrate what the MH CPP, practicing at the top of their license, can achieve as a core member in MH team-based care by improved access, clinical outcomes and cost effectiveness when integrated into MH teams across practice settings. VA has a significant opportunity to re-deploy or add trained MH CPP as a key member of the team and as a primary MH Provider. The supply of MH CPP in most geographic areas is ample, and VA produces over 600 post-graduate trained clinical pharmacy residents each year, 87 with PGY2 Psychiatric Pharmacy training, which are ready for hiring in July of each year.

The PBM CPPO infrastructure utilized to deploy the CRVA CPS practice expansion is a unique and robust resource that may be successfully used to scale national Pain Management CPS practice expansion. MH CPP have specialized training and expertise in providing care for Veterans with complex medications regimens. As such, MH CPP represent a key resource for complex Veteran care and as part of team-based care.

Questions related to this guidance may be directed to the Clinical Pharmacy Practice Office (CPPO) at VHAPBH Clinical Pharmacy Practice Office (CPPO) ClinicalPharmacyPracticeOfficeCPPO@va.gov.
REFERENCES


5. Office of Mental Health and Suicide Prevention Mental Health Continuum Workgroup Report.


